Pharmaceutical intermediates
Enasidenib Mesylate Intermediates
4 pharmaceutical intermediates for Enasidenib Mesylate. Indication: Leukemia, Myeloid, Acute.
About Enasidenib Mesylate
- Originator
- Celgene Corporation; Agios Pharmaceuticals Inc; Laboratoires Servier
- Indication
- Leukemia, Myeloid, Acute
- Approved Date
- 08/01/2017
- DS/DP
- 06/21/2030
Available intermediates
4 intermediates currently listed for Enasidenib Mesylate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 4-Amino-2-trifluoromethylpyridine | 147149-98-2 | / | / |
| 2-Trifluoromethyl-6-pyridinecarboxylic acid | 131747-42-7 | / | / |
| 6-Trifluoromethyl-pyridine-2-carboxylic acid methyl ester | 155377-05-2 | / | / |
| 6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazine-2,4(1H,3H)-dione | 1446507-38-5 | / | / |
Building toward Enasidenib Mesylate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →